Jane Street Group, LLC Chemo Centryx, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

Shares

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $1.44 Million - $3.37 Million	-65,074 Reduced 89.27%	7,822 $404,000
Q2 2022 Aug 16, 2022	SELL	$15.36 - $27.51 $644,121 - $1.15 Million	-41,935 Reduced 36.52%	72,896 $1.81 Million
Q1 2022 May 17, 2022	BUY	$22.22 - $39.12 $586,274 - $1.03 Million	26,385 Added 29.83%	114,831 $2.88 Million
Q4 2021 Feb 15, 2022	BUY	$18.38 - $40.5 $634,643 - $1.4 Million	34,529 Added 64.04%	88,446 $3.22 Million
Q3 2021 Nov 16, 2021	SELL	$13.18 - $19.83 $3.44 Million - $5.17 Million	-260,862 Reduced 82.87%	53,917 $921,000
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $2.87 Million - $15.2 Million	298,996 Added 1894.42%	314,779 $4.22 Million
Q1 2021 May 18, 2021	SELL	$49.53 - $68.4 $1.55 Million - $2.14 Million	-31,353 Reduced 66.52%	15,783 $809,000
Q4 2020 Feb 17, 2021	SELL	$47.25 - $65.16 $988,800 - $1.36 Million	-20,927 Reduced 30.75%	47,136 $2.92 Million
Q3 2020 Nov 17, 2020	BUY	$46.35 - $61.69 $2.08 Million - $2.77 Million	44,899 Added 193.83%	68,063 $3.73 Million
Q2 2020 Aug 17, 2020	BUY	$38.58 - $65.07 $541,547 - $913,387	14,037 Added 153.8%	23,164 $1.33 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $298,726 - $463,469	9,127 New	9,127 $367,000
Q2 2018 Aug 15, 2018	SELL	$10.62 - $13.98 $153,235 - $201,717	-14,429 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$5.9 - $14.99 $85,131 - $216,290	14,429 New	14,429 $196,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.